Novartis (NVS) Competitors

Novo Nordisk A/S (NYSE:NVO) and Novartis (NYSE:NVS) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment, earnings and community ranking.

Does the MarketBeat Community favor NVO or NVS?

Novartis received 102 more outperform votes than Novo Nordisk A/S when rated by MarketBeat users. However, 61.88% of users gave Novo Nordisk A/S an outperform vote while only 60.94% of users gave Novartis an outperform vote.

Company	Underperform	Outperform
Novo Nordisk A/S	Outperform Votes 427 61.88%	Underperform Votes 263 38.12%
Novartis	Outperform Votes 529 60.94%	Underperform Votes 339 39.06%

Do insiders and institutionals believe in NVO or NVS?

11.5% of Novo Nordisk A/S shares are owned by institutional investors. Comparatively, 13.1% of Novartis shares are owned by institutional investors. 0.1% of Novo Nordisk A/S shares are owned by insiders. Comparatively, 0.0% of Novartis shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Is NVO or NVS more profitable?

Novartis has a net margin of 35.96% compared to Novo Nordisk A/S's net margin of 35.03%. Novo Nordisk A/S's return on equity of 86.32% beat Novartis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novo Nordisk A/S	35.03%	86.32%	27.42%
Novartis	35.96%	34.80%	15.13%

Which has more risk and volatility, NVO or NVS?

Novo Nordisk A/S has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500. Comparatively, Novartis has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500.

Do analysts prefer NVO or NVS?

Novo Nordisk A/S presently has a consensus target price of $140.20, indicating a potential upside of 78.06%. Novartis has a consensus target price of $121.50, indicating a potential upside of 24.61%. Given Novo Nordisk A/S's stronger consensus rating and higher probable upside, equities analysts clearly believe Novo Nordisk A/S is more favorable than Novartis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novo Nordisk A/S	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	3.00
Novartis	2 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.78

Does the media prefer NVO or NVS?

In the previous week, Novo Nordisk A/S had 43 more articles in the media than Novartis. MarketBeat recorded 63 mentions for Novo Nordisk A/S and 20 mentions for Novartis. Novo Nordisk A/S's average media sentiment score of 0.57 beat Novartis' score of 0.47 indicating that Novo Nordisk A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novo Nordisk A/S	29 Very Positive mention(s)	7 Positive mention(s)	16 Neutral mention(s)	9 Negative mention(s)	1 Very Negative mention(s)	Positive
Novartis	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	5 Negative mention(s)	0 Very Negative mention(s)	Neutral

Is NVO or NVS a better dividend stock?

Novo Nordisk A/S pays an annual dividend of $0.72 per share and has a dividend yield of 0.9%. Novartis pays an annual dividend of $2.43 per share and has a dividend yield of 2.5%. Novo Nordisk A/S pays out 23.3% of its earnings in the form of a dividend. Novartis pays out 28.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.

Which has higher valuation and earnings, NVO or NVS?

Novartis has higher revenue and earnings than Novo Nordisk A/S. Novartis is trading at a lower price-to-earnings ratio than Novo Nordisk A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novo Nordisk A/S	$33.71B	10.48	$12.15B	$3.09	25.48
Novartis	$45.44B	4.39	$14.85B	$8.61	11.32

Summary

Novo Nordisk A/S beats Novartis on 13 of the 21 factors compared between the two stocks.